ENXTPA:IVABiotechs
A Look At Inventiva (ENXTPA:IVA) Valuation As NATiV3 Enrollment Completes And Odiparcil Rights Are Sold
Inventiva (ENXTPA:IVA) is back on investors’ radars after completing enrollment in its global Phase III NATiV3 trial for lanifibranor in MASH, while selling odiparcil rights to focus resources and potential future milestone income.
See our latest analysis for Inventiva.
At a share price of €4.72, the stock has a 90 day share price return of 19.8% and a 1 year total shareholder return of 82.95%, suggesting momentum has been building as investors focus on the NATiV3 progress and portfolio...